[The Chinese clinical expert consensus for the BCMA bispecific T cell engager in the treatment of multiple myeloma (2025)]
{{output}}
Multiple myeloma is an incurable disease. The bispecific T cell engager, one of the immune therapies targeting tumor cell surface antigens, has shown promising clinical efficacy. However, bispecific T cell engager therapy has a unique anti-myeloma mechanism an... ...
